Skip to main content

Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age

In brief

Semaglutide cut BMI by 13.5% in children aged 6 to 11 with obesity

In a randomized trial of 167 children, BMI fell by an average of 13.5% after 68 weeks of weekly semaglutide, while it rose 2.7% with placebo; 79% on semaglutide moved to a lower BMI category. Gastrointestinal effects were more common, though only one child stopped treatment for them, and it remains unclear how weight changes after treatment ends.

Journal
The New England journal of medicine (Q1)
Published
16 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Ania M Jastreboff, Nina M Harder-Lauridsen, Michelle Van Name, Antje Körner, Aaron S Kelly, Daniel Weghuber, et al.
PMID
43037562
DOI
10.1056/NEJMoa2604058

Why clinicians should know about it

Abstract

BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to <12 years of age) with obesity. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide or placebo for a period of 104 weeks, after which participants stopped taking semaglutide or placebo for a 7-week washout period. Both groups received counseling for lifestyle modification. The primary end point was the percent change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. RESULTS: Among 167 children who underwent randomization, 112 were assigned to receive semaglutide and 55 to receive placebo. At week 68, the mean percent change in BMI was -13.5% with semaglutide and 2.7% with placebo (estimated between-group difference, -16.2 percentage points; 95% confidence interval [CI], -19.4 to -12.9; P<0.001). The percent change in BMI at week 104 was -9.4% with semaglutide and 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3). At week 68, a reduction in BMI category had occurred in 79% of the participants in the semaglutide group and in 23% of those in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001), with the BMI below the threshold for obesity (the 95th percentile for age and sex) in 38% of the participants who received semaglutide and in 2% of those who received placebo. Adverse events occurred in 96% of the participants receiving semaglutide and in 93% of those receiving placebo. Gastrointestinal adverse events were the most common, occurred more frequently with semaglutide than with placebo, and led to discontinuation in 1 participant in the semaglutide group. CONCLUSIONS: Among children (6 to <12 years of age) with obesity, treatment with semaglutide for 68 weeks resulted in a significantly greater mean percent reduction in BMI than placebo. (Funded by Novo Nordisk; STEP Young ClinicalTrials.gov number, NCT05726227.).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.